Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

USFDA granted Fast Track designation to GW Pharmaceuticals Plc's investigational cannabidiol product


Friday, 6 Jun 2014 02:00am EDT 

GW Pharmaceuticals Plc:Says the USFDA has granted fast track designation to GW's investigational cannabidiol (CBD) product, Epidiolex, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. 

Company Quote

408.5
-10.0 -2.39%
11:38am EDT